...Okay, hi, everyone. I'm Brian Abrams, one of the Senior Biotech Analysts at RBC Capital Markets. Our next featured company, Regeneron, has always been known for its R&D engine, and there's a lot more coming from their pipeline, really over the next 6 to 12 months and beyond. And the architect of that has been their Board co-Chair, President, and CSO, George Yancopoulos. So we're really pleased to have George with us today, and alongside him on the stage, Mark Hudson, Senior Director of IR for Regeneron. So thanks again for joining us and looking forward to the discussion. George Yancopoulos ...